论文部分内容阅读
目的：观察载阿苯达唑（ABZ）的抗泡球蚴抗体的免疫脂质体对小鼠继发性泡球蚴病的疗效。方法：观察游离的、脂质体运载与免疫脂质体运载的ABZ（12．5、25和50mg／kg）对小鼠腹腔泡球蚴增殖的抑制。结果：免疫脂质体治疗抑制率高于脂质体，后者又高于游离ABZ，高剂量时3组抑制率分别为87．8％、65．2％和17.7％，组间比较差异显著（P＜0.01）；肝和腹腔泡球蚴摄取免疫脂质体的量比单纯脂质体高2．4倍（P＜0．01）。结论：免疫脂质体作载体可明显提高ABZ对泡球蚴病的疗效。
OBJECTIVE: To observe the therapeutic effect of anti-Echinococcus antibody containing immunized liposomal albendazole (ABZ) on secondary alveolar hydatid disease in mice. Methods: The inhibitory effect of ABZ (12.5, 25 and 50 mg / kg) on the proliferation of cysticercosis in mice peritoneal cavity was observed by using free liposome and immunoliposome. Results: The inhibition rate of immunoliposome therapy was higher than that of liposome, which was higher than that of free ABZ. The inhibitory rates of three groups at high dose were 87.8%, 65.2% and 17.7%, respectively, with significant difference between the two groups (P <0.01). The amount of immunoliposomes in the liver and peritoneal larvae was 2.4 times higher than that in pure liposomes (P <0.01). Conclusion: Immunoliposomes can significantly improve the efficacy of ABZ on alveolar echinococcosis.